Evidence map›Paper›PMID 38854702›Full record

ReviewF1000Research2023

COVID-19 in the Arab countries: Three-year study.

Nasar Alwahaibi, Muna Al Maskari, Samiya Al-Jaaidi, Buthaina Al Dhahli, Halima Al Issaei, Shadia Al Bahlani

Abstract readReview
In one paragraph

Review in F1000Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nasar AlwahaibiDepartment of Biomedical Science, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Muscat Governorate, Oman.ORCID https://orcid.org/0000-0002-9421-0951
Muna Al MaskariDepartment of Biomedical Science, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Muscat Governorate, Oman.
Samiya Al-JaaidiDepartment of Biology, College of Science, Sultan Qaboos University, Muscat, Muscat Governorate, Oman.
Buthaina Al DhahliDepartment of Biomedical Science, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Muscat Governorate, Oman.
Halima Al IssaeiDepartment of Biomedical Science, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Muscat Governorate, Oman.
Shadia Al BahlaniDepartment of Biomedical Science, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Muscat Governorate, Oman.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Twenty-two Arab countries share a common language, history, and culture. Nevertheless, governmental policies, healthcare systems, and resources differ from one Arab country to another. We have been following Coronavirus (COVID-19) from the beginning in each Arab country. In the present study, we aimed to assess the prevalence of COVID-19 in the Arab world and to compare these findings with other significantly affected countries. Methods: Websites of the World Health Organization, World COVID-vaccinations tracker, Worldometer, and Ministries of Health were used to extract COVID-19 data in all Arab countries between the period January 2020 to December 2022. Results: All Arab countries had 14,218,042 total confirmed COVID-19 cases, 13,384,924 total recovered cases and 173,544 total related deaths. The trend demonstrated that the third quarter of 2021 recorded the highest death toll and the first quarter of 2022 recorded the highest number of confirmed and recovered cases. Compared to the top 15 affected countries, the Arab world ranked last as it had the lowest overall incidence per million population (PMP) of 31,609. The data on total deaths PMP showed that India had the lowest number of deaths with only 377 cases followed by the Arab world with 386 cases. Conclusions: Although the number of confirmed, death, and recovered cases of COVID-19 have greatly reduced in the last quarter of 2022 in most Arab countries, many Arab countries still need to re-campaign about COVID-19 vaccines and raise awareness programs about boosters. COVID-19 has had a relatively smaller impact on Arab countries than on other countries that have been significantly affected.

Indexed as

COVID-19SARS-CoV-2Arab WorldHumansIncidenceMiddle EastPrevalenceArab countriesconfirmedcoronavirusCOVID-19COVID-19 vaccinesdeathrecovered

Identifiers

PMID38854702
PMCPMC11157493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.